Literature DB >> 22102947

Vein of galen aneurysmal malformation : endovascular management of 6 cases in a single institute.

Jung Hyeon Moon1, Won-Sang Cho, Hyun-Seung Kang, Jeong Eun Kim, Seung Jin Lee, Moon Hee Han.   

Abstract

OBJECTIVE: The aim of this study was to analyze the treatment outcome of patients with vein of Galen aneurysmal malformations (VGM).
METHODS: Clinical and angiographic data of six consecutive patients with VGM were retrospectively reviewed. VGMs were angiographically classified by Yasargil's method. Treatment outcomes were evaluated.
RESULTS: Mean age at initial treatment was 4.4±5.7 months. Angiographic types of VGMs were type II in two patients and type III in four. Three patients had cardiac symptoms and the others were asymptomatic. Two patients were treated with transvenous embolization, three with transarterial embolization, and one was managed conservatively. Two patients died due to venous hypertension few days after transvenous approach. Of three patients who were transarterially embolized, one was completely occluded with Onyx and two were incompletely occluded. During the follow-up period (range, one to six years) two of three patients treated with transarterial approach were asymptomatic and the other showed mild symptoms. One patient who was managed conservatively showed normal performance.
CONCLUSION: Transarterial embolization of VGMs may be better than transvenous approach in terms of the treatment outcome and complication. Further studies are needed because of the rarity of the disease and rapid advancement of endovascular techniques.

Entities:  

Keywords:  Endovascular treatment; Transarterial embolization; Transvenous embolization; Vein of Galen aneurysmal malformation

Year:  2011        PMID: 22102947      PMCID: PMC3218176          DOI: 10.3340/jkns.2011.50.3.191

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  11 in total

1.  Diagnosis and management of vein of galen aneurysmal malformations.

Authors:  Philippe Gailloud; Declan P O'Riordan; Ingrid Burger; Olivier Levrier; George Jallo; Rafael J Tamargo; Kieran J Murphy; Christoph U Lehmann
Journal:  J Perinatol       Date:  2005-08       Impact factor: 2.521

2.  Congestive cardiac manifestations from cerebrocranial arteriovenous shunts. Endovascular management in 30 children.

Authors:  R Garcia-Monaco; D De Victor; C Mann; A Hannedouche; K Terbrugge; P Lasjaunias
Journal:  Childs Nerv Syst       Date:  1991-02       Impact factor: 1.475

3.  Giant arteriovenous malformations of infancy and childhood.

Authors:  D M Long; E L Seljeskog; S N Chou; L A French
Journal:  J Neurosurg       Date:  1974-03       Impact factor: 5.115

Review 4.  The management of vein of Galen aneurysmal malformations.

Authors:  Pierre L Lasjaunias; Soke M Chng; Marina Sachet; Hortensia Alvarez; Georges Rodesch; Ricardo Garcia-Monaco
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

5.  Vein of Galen aneurysmal malformation: diagnosis and treatment of 13 children with extended clinical follow-up.

Authors:  Blaise V Jones; William S Ball; Thomas A Tomsick; Justin Millard; Kerry R Crone
Journal:  AJNR Am J Neuroradiol       Date:  2002 Nov-Dec       Impact factor: 3.825

Review 6.  Cerebral arteriovenous malformations in children. Management of 179 consecutive cases and review of the literature.

Authors:  P Lasjaunias; F Hui; M Zerah; R Garcia-Monaco; V Malherbe; G Rodesch; A Tanaka; H Alvarez
Journal:  Childs Nerv Syst       Date:  1995-02       Impact factor: 1.475

Review 7.  Aneurysms of the vein of Galen: embryonic considerations and anatomical features relating to the pathogenesis of the malformation.

Authors:  C A Raybaud; C M Strother; J K Hald
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

8.  Successful treatment of neonatal aneurysmal dilatation of the vein of Galen: the role of prenatal diagnosis and trans-arterial embolization.

Authors:  Y Yamashita; T Abe; N Ohara; T Maruoka; O Toyoda; O Inoue; K Kojima; H Kato
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

9.  Confirmation of communication between deep venous drainage and the vein of galen after treatment of a vein of Galen aneurysmal malformation in an infant presenting with severe pulmonary hypertension.

Authors:  P Gailloud; D P O'riordan; I Burger; C U Lehmann
Journal:  AJNR Am J Neuroradiol       Date:  2006-02       Impact factor: 3.825

10.  Percutaneous transvenous catheterization and embolization of vein of galen aneurysms.

Authors:  A Casasco; P Lylyk; J E Hodes; G Kohan; A Aymard; J J Merland
Journal:  Neurosurgery       Date:  1991-02       Impact factor: 4.654

View more
  4 in total

1.  Superselective transvenous embolization with Onyx and n-BCA for vein of Galen aneurysmal malformations with restricted transarterial access: safety, efficacy, and technical aspects.

Authors:  Kirill Orlov; Anton Gorbatykh; Vadim Berestov; Timur Shayakhmetov; Dmitry Kislitsin; Pavel Seleznev; Nikolay Strelnikov
Journal:  Childs Nerv Syst       Date:  2017-07-08       Impact factor: 1.475

Review 2.  Endovascular Treatment of Vein of Galen Malformations: A Systematic Review and Meta-Analysis.

Authors:  W Brinjikji; T Krings; M H Murad; A Rouchaud; D Meila
Journal:  AJNR Am J Neuroradiol       Date:  2017-10-05       Impact factor: 3.825

3.  Adjuvant Coil Assisted Glue Embolization of Vein of Galen Aneurysmal Malformation in Pediatric Patients.

Authors:  Dong Joon Kim; Dae Chul Suh; Byung Moon Kim; Dong Ik Kim
Journal:  Neurointervention       Date:  2018-03-02

Review 4.  Outcomes of endovascular embolization for Vein of Galen malformations: An individual participant data meta-analysis.

Authors:  Cody Savage; Andrew T Hale; Matthew S Parr; Alexander Hedaya; Benjamin W Saccomano; Georges Bouobda Tsemo; Muhammad U Hafeez; Omar Tanweer; Peter Kan; Laurent J Solomon; Dan Meila; Peter B Dirks; Jeffrey P Blount; James M Johnston; Brandon G Rocque; Curtis J Rozzelle; Kartik Bhatia; Prakash Muthusami; Timo Krings; Jesse Jones
Journal:  Front Pediatr       Date:  2022-09-30       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.